Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:e1-e8

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vehmaan-Kreula, P.
Right arrow Articles by Kovanen, P. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vehmaan-Kreula, P.
Right arrow Articles by Kovanen, P. T.
Related Collections
Right arrow Pathophysiology
Right arrow Acute coronary syndromes
Right arrow Other Vascular biology
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:e1.)
© 2001 American Heart Association, Inc.


Vascular Biology

Chlamydia pneumoniae Proteins Induce Secretion of the 92-kDa Gelatinase by Human Monocyte– Derived Macrophages

Pirjo Vehmaan-Kreula; Mirja Puolakkainen; Matti Sarvas; Howard G. Welgus; Petri T. Kovanen

From the Wihuri Research Institute (P.V.-K., P.T.K.); the Haartman Institute (M.P.), Department of Virology, University of Helsinki; and the National Public Health Institute (M.S.), Department of Vaccines, Helsinki, Finland; and Parke-Davis Pharmaceuticals Research (H.G.W.), Ann Arbor, Mich.

Correspondence to Petri T. Kovanen, MD, PhD, Wihuri Research Institute, Kalliolinnantie 4, 00140 Helsinki, Finland. E-mail Petri.Kovanen{at}wri.fi

AbstractChlamydia pneumoniae, an intracellular Gram-negative respiratory bacterium, and macrophages are present in inflammatory tissue sites such as atherosclerotic lesions, where abnormal degradation of the extracellular matrix takes place. To evaluate the potential of C pneumoniae for participation in matrix destruction, we studied the effect of this bacterium on the production of 3 matrix-degrading metalloproteinases, 92-kDa gelatinase, interstitial collagenase-1, and stromelysin-1, and their natural inhibitor TIMP-1 (tissue inhibitor of metalloproteinases-1) by human monocyte–derived macrophages differentiated in vitro. Spontaneous production of collagenase and stromelysin by these cells was minimal and was not influenced by C pneumoniae. In contrast, the cells secreted substantial basal quantities of 92-kDa gelatinase, the secretion of which was stimulated (on average, 2.5-fold) by C pneumoniae. C pneumoniae regulated the expression of 92-kDa gelatinase by macrophages at the pretranslational level. Macrophages secreted only small quantities of TIMP-1. The chlamydial proteins Omp2, MOMP, and HSP60 were also found to participate in the induction of 92-kDa gelatinase by C pneumoniae. Denaturation of chlamydial proteins by boiling reduced 92-kDa gelatinase secretion only partially (by 35%), suggesting that the heat-stabile lipopolysaccharide molecules also stimulate secretion of the enzyme. The results show that production of 92-kDa gelatinase by human macrophages is selectively upregulated by C pneumoniae, which suggests that these bacteria, when present in a macrophage-containing inflammatory environment, actively participate in the destruction of the extracellular matrix.


Key Words: humans • monocytes • macrophages • cellular activation • inflammatory mediators




This article has been cited by other articles:


Home page
CVIHome page
U. Airaksinen, T. Penttila, E. Wahlstrom, J. M. Vuola, M. Puolakkainen, and M. Sarvas
Production of Chlamydia pneumoniae Proteins in Bacillus subtilis and Their Use in Characterizing Immune Responses in the Experimental Infection Model
Clin. Vaccine Immunol., May 1, 2003; 10(3): 367 - 375.
[Abstract] [Full Text] [PDF]